319 related articles for article (PubMed ID: 18469554)
1. Consolidation treatment with rituximab induces complete and persistent remission of mixed type Evans syndrome.
Rodella E; Pacquola E; Bianchini E; Ramazzina E; Paolini R
Blood Coagul Fibrinolysis; 2008 Jun; 19(4):315-8. PubMed ID: 18469554
[TBL] [Abstract][Full Text] [Related]
2. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study.
Dierickx D; Verhoef G; Van Hoof A; Mineur P; Roest A; Triffet A; Kentos A; Pierre P; Boulet D; Bries G; LĂȘ PQ; Janssens A; Delannoy A
J Intern Med; 2009 Nov; 266(5):484-91. PubMed ID: 19549092
[TBL] [Abstract][Full Text] [Related]
3. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.
Koulova L; Alexandrescu D; Dutcher JP; O'Boyle KP; Eapen S; Wiernik PH
Am J Hematol; 2005 Jan; 78(1):49-54. PubMed ID: 15609292
[TBL] [Abstract][Full Text] [Related]
4. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
[TBL] [Abstract][Full Text] [Related]
5. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
Zaja F; Iacona I; Masolini P; Russo D; Sperotto A; Prosdocimo S; Patriarca F; de Vita S; Regazzi M; Baccarani M; Fanin R
Haematologica; 2002 Feb; 87(2):189-95. PubMed ID: 11836170
[TBL] [Abstract][Full Text] [Related]
6. Rituximab for refractory Evans syndrome and other immune-mediated hematologic diseases.
Mantadakis E; Danilatou V; Stiakaki E; Kalmanti M
Am J Hematol; 2004 Nov; 77(3):303-10. PubMed ID: 15495242
[TBL] [Abstract][Full Text] [Related]
7. A patient with mixed type Evans syndrome: efficacy of rituximab treatment.
Park CY; Chung CH
J Korean Med Sci; 2006 Dec; 21(6):1115-6. PubMed ID: 17179698
[TBL] [Abstract][Full Text] [Related]
8. Rituximab therapy for childhood Evans syndrome.
Bader-Meunier B; Aladjidi N; Bellmann F; Monpoux F; Nelken B; Robert A; Armari-Alla C; Picard C; Ledeist F; Munzer M; Yacouben K; Bertrand Y; Pariente A; Chaussé A; Perel Y; Leverger G
Haematologica; 2007 Dec; 92(12):1691-4. PubMed ID: 18055994
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of a patient with mixed warm and cold antibody mediated Evans syndrome and glucose intolerance.
Jubinsky PT; Rashid N
Pediatr Blood Cancer; 2005 Sep; 45(3):347-50. PubMed ID: 15704210
[TBL] [Abstract][Full Text] [Related]
10. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.
Schweizer C; Reu FJ; Ho AD; Hensel M
Ann Hematol; 2007 Oct; 86(10):711-7. PubMed ID: 17622529
[TBL] [Abstract][Full Text] [Related]
11. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome.
Shanafelt TD; Madueme HL; Wolf RC; Tefferi A
Mayo Clin Proc; 2003 Nov; 78(11):1340-6. PubMed ID: 14601692
[TBL] [Abstract][Full Text] [Related]
12. [Rituximab instead of splenectomy in 4 children with chronic or refractory autoimmune haemolytic anaemia].
van Daalen ST; van Dijken PJ; Tamminga RY; Brons PP
Ned Tijdschr Geneeskd; 2005 Oct; 149(42):2350-4. PubMed ID: 16261716
[TBL] [Abstract][Full Text] [Related]
13. Anti-CD20 monoclonal antibody therapy in refractory immune thrombocytopenic purpura.
Delgado J; Bustos JG; Jimenez-Yuste V; Hernandez-Navarro F
Haematologica; 2002 Feb; 87(2):215-6. PubMed ID: 11836172
[TBL] [Abstract][Full Text] [Related]
14. Rituximab in the treatment of relapsing idiopathic thrombocytopenic purpura.
Riksen NP; Keuning JJ; Vreugdenhil G
Neth J Med; 2003 Jul; 61(7):262-5. PubMed ID: 14567524
[TBL] [Abstract][Full Text] [Related]
15. Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results.
Medeot M; Zaja F; Vianelli N; Battista M; Baccarani M; Patriarca F; Soldano F; Isola M; De Luca S; Fanin R
Eur J Haematol; 2008 Sep; 81(3):165-9. PubMed ID: 18510702
[TBL] [Abstract][Full Text] [Related]
16. Prompt and sustained response of a steroid-refractory autoimmune hemolytic anemia to a rituximab-based therapy in a chronic lymphocytic leukemia patient.
Gentile M; Lucia E; Iorio C; Vigna E; Mazzone C; Morelli R; Bisconte MG; Gentile C; Morabito F
Cancer Chemother Pharmacol; 2008 Sep; 62(4):741-3. PubMed ID: 18064461
[TBL] [Abstract][Full Text] [Related]
17. Partial response to anti-CD20 monoclonal antibody treatment of severe immune thrombocytopenic purpura in a patient with common variable immunodeficiency.
Carbone J; Escudero A; Mayayo M; Ballesteros M; Perez-Corral A; Sanchez-Ramon S; Sarmiento E; Micheloud D; Fernandez-Cruz E
Ann N Y Acad Sci; 2005 Jun; 1051():666-71. PubMed ID: 16127007
[TBL] [Abstract][Full Text] [Related]
18. Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults.
Provan D; Butler T; Evangelista ML; Amadori S; Newland AC; Stasi R
Haematologica; 2007 Dec; 92(12):1695-8. PubMed ID: 18055995
[TBL] [Abstract][Full Text] [Related]
19. Rituximab in the treatment of refractory autoimmune cytopenias in adults.
Narat S; Gandla J; Hoffbrand AV; Hughes RG; Mehta AB
Haematologica; 2005 Sep; 90(9):1273-4. PubMed ID: 16154853
[TBL] [Abstract][Full Text] [Related]
20. Treatment of an infant with severe acute refractory immune thrombocytopenic purpura using combination therapy including rituximab.
Iesato K; Hatakeyama N; Yamamoto M; Hori T; Inazawa N; Tsutsumi H; Suzuki N
Pediatr Blood Cancer; 2009 Aug; 53(2):203-5. PubMed ID: 19301247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]